These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 35836089)
41. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance. Sasaki R; Shiino C; Imawari M; Bentley R; Cai B; Yoshida M; Afdhal N Hepatol Res; 2019 Oct; 49(10):1169-1181. PubMed ID: 31228221 [TBL] [Abstract][Full Text] [Related]
43. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures. Gallo P; Terracciani F; Di Pasquale G; Esposito M; Picardi A; Vespasiani-Gentilucci U World J Gastroenterol; 2022 Aug; 28(30):4061-4074. PubMed ID: 36157107 [TBL] [Abstract][Full Text] [Related]
44. Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure. Satapathy SK; Sundaram V; Shiffman ML; Jamieson BD Medicine (Baltimore); 2023 Oct; 102(40):e35208. PubMed ID: 37800793 [TBL] [Abstract][Full Text] [Related]
45. Is platelet monitoring during 7-day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase IIIb open-label study. Numata K; Tanaka K; Katsube T; Ochiai T; Fukuhara T; Kano T; Osaki Y; Izumi N; Imawari M Hepatol Res; 2020 Oct; 50(10):1141-1150. PubMed ID: 32609920 [TBL] [Abstract][Full Text] [Related]
46. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States. Dieterich DT; Bernstein D; Flamm S; Pockros PJ; Reau N Aliment Pharmacol Ther; 2020 Oct; 52(8):1311-1322. PubMed ID: 32813292 [TBL] [Abstract][Full Text] [Related]
48. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching. Furuichi Y; Takeuchi H; Yoshimasu Y; Kasai Y; Abe M; Itoi T Hepatol Res; 2020 Sep; 50(9):1062-1070. PubMed ID: 32510789 [TBL] [Abstract][Full Text] [Related]
49. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Estcourt LJ; Stanworth S; Doree C; Trivella M; Hopewell S; Blanco P; Murphy MF Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010984. PubMed ID: 26505729 [TBL] [Abstract][Full Text] [Related]
50. Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study. Gallo P; De Vincentis A; Terracciani F; Falcomatà A; Pace Palitti V; Russello M; Vignone A; Alvaro D; Tortora R; Biolato M; Pompili M; Calvaruso V; Marzia V; Tizzani M; Caneglias A; Frigo F; Gesualdo M; Marzano A; Rosato V; Claar E; Villani R; Izzi A; Cozzolongo R; Cozzolino A; Airoldi A; Mazzarelli C; Distefano M; Iegri C; Fagiuoli S; Messina V; Ragone E; Sacco R; Cacciatore P; Masutti F; Crocé SL; Moretti A; Flagiello V; Di Pasquale G; Picardi A; Vespasiani-Gentilucci U J Clin Med; 2024 Jul; 13(13):. PubMed ID: 38999529 [No Abstract] [Full Text] [Related]
51. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Estcourt LJ; Stanworth SJ; Doree C; Hopewell S; Trivella M; Murphy MF Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010983. PubMed ID: 26576687 [TBL] [Abstract][Full Text] [Related]
52. Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: A systematic review and meta-analysis. Rose PD; Au M; Woodman RJ; Tee D; Chinnaratha MA Dig Liver Dis; 2021 Nov; 53(11):1396-1403. PubMed ID: 34373229 [TBL] [Abstract][Full Text] [Related]
53. Management of Thrombocytopenia in Patients with Chronic Liver Disease. Saab S; Brown RS Dig Dis Sci; 2019 Oct; 64(10):2757-2768. PubMed ID: 31011942 [TBL] [Abstract][Full Text] [Related]
54. Pathogen-reduced platelets for the prevention of bleeding. Estcourt LJ; Malouf R; Hopewell S; Trivella M; Doree C; Stanworth SJ; Murphy MF Cochrane Database Syst Rev; 2017 Jul; 7(7):CD009072. PubMed ID: 28756627 [TBL] [Abstract][Full Text] [Related]
55. Safety and effectiveness of lusutrombopag in patients who have chronic liver disease with thrombocytopenia and undergoing invasive procedures: Real-world post-marketing surveillance in Japan. Yoshiji H; Suzuki J; Imasaki M; Tsukimura E; Miyano M; Kurosaki M Hepatol Res; 2023 Nov; 53(11):1105-1116. PubMed ID: 37497574 [TBL] [Abstract][Full Text] [Related]
56. Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation. Desborough M; Estcourt LJ; Doree C; Trivella M; Hopewell S; Stanworth SJ; Murphy MF Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010982. PubMed ID: 27548292 [TBL] [Abstract][Full Text] [Related]
57. Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study. Ding JN; Feng TT; Sun W; Cai XY; Zhang Y; Zhao WF World J Gastrointest Surg; 2022 Nov; 14(11):1260-1271. PubMed ID: 36504518 [TBL] [Abstract][Full Text] [Related]
58. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762 [TBL] [Abstract][Full Text] [Related]